Michael Jeltsch: List of Publications

This list is also available from Thomson Reuters (excluding theses, books and patents):
http://www.researcherid.com/rid/I-5340-2012)

Impact factors are from Thomson Reuters with the exception of journals not listed by the Web of Science (marked by an asterisk*),
for which they are
calculated based on Scopus data. Updated on April 7th, 2016.

I. Original Articles

 

Impact factor
(2014)

Citations

Dashkevich A, Raissadati A, Syrjälä SO, Zarkada G, Keränen MAI, Tuuminen R, Krebs R, Anisimov A, Jeltsch M, Leppänen V-M, Alitalo K, Nykänen AI, Lemström, KB. Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts: Lymphatic Endothelial VEGFR3 Controls Rejection. Am J Transplant. 2015; in press.

5.683

0

Roukens MG, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppänen V-M, Bos FL, Alitalo K, Schulte-Merker S, Schulte D. Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res. 2015; 116 (10): 1660-1669.

11.019

1

Batchu KC, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysis. J Biol Chem. 2015; 290 (16): 10093-10103.

4.573

0

Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, Kivelä R, Ortega S, Kärpanen T, Alitalo K. CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C Activation. Circulation. 2014; 129 (19): 1962–71.

15.073

23

Anisimov A, Leppanen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, Kaijalainen S, Alitalo K. The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands. Sci Signal. 2013; 6 (282): ra52.

6.279

8

Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, Orsenigo F, Gaál EI, Holopainen T, Koh YJ, Tammela T, Korpisalo P, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Dejana E, Koh GY, Choi C, Saharinen P, et al. Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis. Circulation. 2013; 127 (4): 424–34.

15.073

15

Leppänen V-M, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, Markovic-Mueller S, Stuttfeld E, Goldie KN, Ballmer-Hofer K, Alitalo K. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. PNAS. 2013; 110 (32): 12960–5.

9.674

12

Villefranc JA, Nicoli S, Bentley K, Jeltsch M, Zarkada G, Moore JC, Gerhardt H, Alitalo K, Lawson ND. A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development. 2013; 140 (7): 1497–506.

6.462

22

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, Nykanen AI, Lemstrom KB. Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. Am J Pathol. 2012; 181 (5): 1607–20.

4.591

11

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, Koskinen PK, Nykanen AI, Lemstrom KB. VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. J Heart Lung Transpl. 2011; 30 (4): S118–S118.

6.650

1

Leppanen V-M*, Jeltsch M*, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Ylä-Herttuala S, Ballmer-Hofer K, Alitalo K. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood. 2011; 117 (5): 1507–15. *shared first authorship

10.452

37

Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G, Pietras K. Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE. 2010; 5(11).

3.234

22

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemström KB, Shibuya M, Ylä-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, Alitalo K. Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation. 2010; 122 (17): 1725–33.

15.073

48

Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. PNAS. 2010; 107 (6): 2425–30.

9.674

78

Saharinen P, Helotera H, Miettinen J, Norrmen C, D’Amico G, Jeltsch M, Langenberg T, Vandevelde W, Ny A, Dewerchin M, Carmeliet P, Alitalo K. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Gene Dev. 2010; 24 (9): 875–80.

10.798

12

Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell. 2010; 18 (6): 630–40.

23.523

64

Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, Jeltsch M, Ylä-Herttuala S, Alitalo K. Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle. Circ Res. 2009; 104 (11): 1302–12.

11.019

38

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, Wedge SR, Jurgensmeier JM, Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008; 68 (12): 4754–62.

9.329

65

Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H, Kivela R, Helkamaa T, Merentie M, Jeltsch M, Paavonen K, Andersson LC, Mervaala E, Hassinen IE, Yla-Herttuala S, Oresic M, Alitalo K. Overexpression of Vascular Endothelial Growth Factor-B in Mouse Heart Alters Cardiac Lipid Metabolism and Induces Myocardial Hypertrophy. Circ Res. 2008; 103 (9): 1018–U247.

11.019

55

Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Juan TD, Sievers RE, Chorianopoulos E, Wada H, Vanwildemeersch M, Noel A, Foidart J-M, Springer ML, von Degenfeld G, Dewerchin M, Blau HM, Alitalo K, et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008; 28 (9): 1614–20.

6.008

53

Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K. Enhanced Capillary Formation Stimulated by a Chimeric Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor-C Silk Domain Fusion Protein. Circ Res. 2007; 100 (10): 1460–7.

11.019

10

Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res. 2007; 100 (10): 1468–75.

11.019

19

Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns. J Biol Chem. 2006; 281 (17): 12187–95.

4.573

18

Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006; 20 (9): 1462–72.

5.043

158

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Ylä-Herttuala S, Jackson DG, Alitalo K, McDonald DM. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005; 115 (2): 247–57.

13.262

305

He YL, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65 (11): 4739–46.

9.329

220

Krebs R, Tikkanen JM, Nykanen AI, Wood J, Jeltsch M, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Resp Crit Care. 2005; 171 (12): 1421–9.

12.996

25

Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 161 (6): 1163–77.

9.834

1086

Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2003; 5 (1): 74–80.

20.004

614

Veikkola T, Lohela M, Ikenberg K, Makinen T, Korff T, Saaristo A, Petrova T, Jeltsch M, Augustin HG, Alitalo K. Intrinsic versus micro environmental regulation of lymphatic endothelial cell phenotype and function. FASEB J. 2003; 17 (14): 2006–13.

5.043

56

Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Yla-Herttuala S, Alitalo K. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J. 2002; 16 (9): 1041–9.

5.043

90

Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001; 88 (6): 623–9.

11.089

133

Veikkola T, Jussila L, Mäkinen T, Kärpänen T, Jeltsch M, Petrova T, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via  vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001; 20 (6): 1223- 31.

10.434

398

Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001; 20 (4): 672–82.

10.434

631

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Hakkinen TP, Kivela A, Enholm B, Mansukoski H, Turunen AM, Alitalo K, Yla-Herttuala S. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000; 102 (18): 2262–8.

15.073

92

Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). PNAS. 1998; 95 (2): 548–53.

9.674

758

Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch M, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. PNAS. 1998; 95 (20): 11709–14.

9.674

332

Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 1998; 177 (3): 439–52.

3.839

125

Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 1997; 272 (40): 25176–83.

4.573

126

Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science. 1997; 276 (5317): 1423–5.

33.611

842

Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997; 16 (13): 3898–911.

10.434

480

Oh S-J, Jeltsch M, Birkenhäger R, McCarthy JEG, Weich HA, Christ B, Alitalo K, Wilting J. VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane. Dev Biol. 1997; 188 (1): 96–109.

3.547

344

Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular. Development. 1996; 122 (12): 3829–37.

6.462

418

II. Review Articles

Mattonet K, Jeltsch M. Heterogeneity of the origin of the lymphatic vascular system. [German] [English] Lymphforsch. 2015; 19 (2): 2-5.

1,469*

0

Krebs R, Lackner M, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 2: The role of VEGF-C and VEGF-D in lymphatic system diseases. [German] Vasomed. 2014; 26 (1): 48–50.

0,230*

0

Jeltsch M, Leppanen V-M, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. CSH Perspect Biol. 2013; 5 (9): a009183–a009183.

8.679

24

Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 1. Grundlagen und Embryonalentwicklung. [German] Lymphforsch. 2013; 17 (1): 30–7.

1,469*

0

Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 2. Die Rolle von VEGF-C und VEGF-D bei Krankheiten des Lymphgefäßsystems. [German] Lymphforsch. 2013; 17 (2): 96–104.

1,469*

0

Krebs R, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Fundamentals and embryonic development. [German] Vasomed. 2013; 25 (6): 335–6.

0,230*

0

Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res. 2003; 314 (1): 69–84.

3.565

52

Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotech. 1999; 10 (6): 528–35.

7.117

115

Joukov V, Kaipainen A, Jeltsch M, Pajusola K, Olofsson B, Kumar V, Eriksson U, Alitalo K. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. 1997; 173 (2): 211–5.

3.839

81

III. Meeting Abstracts

Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, Stacker S, Alitalo K. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. Clin Canc Res. 2001; 7 (11): 3762S – 3762S.

8.722

0

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Häkkinen TP, Kivel ä A, Enholm B, Mansukoski H, Turunen A-M, Alitalo K, Ylä-Herttuala S. VEGF-C adenovirus gene transfer reduces intima formation in rabbits. Atherosclerosis Supplements. 2000; 151 (1): 81.

2.293

0

IV. Book Chapters

Saharinen P, Jeltsch M, Santoyo MM, Leppänen V-M, Alitalo K. TIE Receptor Tyrosine Kinase Family. Receptor Tyrosine Kinases: Family and Subfamilies. Springer International Publishing Switzerland; in press.

Mattonet K, Wilting J, Jeltsch M. Die genetischen Ursachen des primären Lymphödems. In: Weissleder H, Schuchhardt C, editors. Erkrankungen des Lymphgefäßsystems. Cologne: Viavital Verlag; 2015. p. 210-29.

Jeltsch M, Alitalo K. VEGF Receptors. In: Watling, K., editor. Sigma-RBI Handbook of Receptor Classification and Signal Transduction. Sigma-Aldrich Co. LLC; 2006. p. 338–9.

IV. Theses

Jeltsch, Michael. VEGFR-3 Ligands and Lymphangiogenesis [Doctoral Thesis]. [Helsinki, Finland]: University of Helsinki; 2002.

Jeltsch, Michael. Functional Analysis of VEGF-B and VEGF-C [Master’s Thesis]. [Helsinki, Finland]: University of Helsinki; 1997.

V. Patents, Patent Applications and Invention Disclosures

Date

Title

Inventors

#

Invention Disclosures

 

 

 

01.02.1016

Rapid generation of  monoclonal antibodies

M. Jeltsch, K. Mattonet, J. Vulli

0534/2015 (to the University of Helsinki)

Patent applications

 

 

 

24.01.2014

Methods and uses related to  ADAMTS3

K. Alitalo, M. Jeltsch, S.K. Jha, D. Tvorogov

PCT/FI2015/050041

12.08.2013
13.08.2014

Therapeutic use of VEGF-C and CCBE1

K. Alitalo, M Jeltsch, A. Anisimov

PCT/FI2014/050620
14756085.8 - 1466

22.03.2012

Modified VEGF-A with improved  angiogenic properties

K. Alitalo, T. Tammela, S. Keskitalo, K. Pajusola, M. Jeltsch, et al.

US20120071406

17.11.2005

Use of VEGF-C or VEGF-D gene or protein to prevent restenosis

K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al.

US20050256075

06.06.2002

Glycosylated VEGF-B, method for increasing the amount of soluble VEGF-B

M. Jeltsch, K. Alitalo,  B. Olofsson, U. Eriksson

US20020068694

Patents

 

 

 

04.06.2013

Use of VEGF-D gene to prevent restenosis

K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al.

US8455453

25.08.2011

Materials and methods involving hybrid VEGF DNAs and proteins

K. Alitalo, M. Jeltsch

US8278098

24.11.2010

VEGFR-2-specific forms of VEGF-D and VEGF-C and uses thereof

K. Alitalo, M. Jeltsch, V.-M. Leppänen, K. Aho, A. Anisimov, D. Tvorogov

WO2012088563

18.06.2009

Growth factor binding constructs materials and methods

K. Alitalo, M. Jeltsch

US7855178

09.02.2006

VEGFR-3 fusion proteins

K. Alitalo, M. Jeltsch

US7422741

25.10.2005

Use of VEGF-C to prevent  restenosis

K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al.

US6958147